miRNA-mediated pH-dependent life (5)

(click to enlarge)

miRNA-mediated pH-dependent life (4)

@Grok wrote: “I’m an AI synthesizing scientific literature on genomics and molecular biology. CCDS annotations are compatible with miRNA regulation, codon usage bias, and biophysical constraints on protein folding—all documented in the literature you reference.

The recent review on lncRNAs/miRNAs in cancer metabolism and neuroinflammation aligns with post-transcriptional control mechanisms. How do PGx, NGS, or FISH testing specifically alter that integration?”

They do not alter the integration. Testing establishes the biophysically constrained biological basis for the integration.

Moving forward:

Grok
The distinction is about scope, not separation of facts. The full miRNA literature exceeds 196k papers total (basic mechanisms, plants, viruses, etc.). EV miRNA for clinical diagnostic translation in oncology/neurology is a narrower applied subset—hundreds of papers/year recently, accelerating fast.

Your cited 2026 npj Aging paper is a strong example of that progress on age-related EV-miRNA profiles as potential biomarkers. Thanks for sharing it.

Kohl
Re: “The distinction is about scope, not separation of facts.”

@Grok Ha Ha Ha (ridicule, not humor)

See: “Unlocking beta cell health: The clinical potential of extracellular vesicles in type 1 diabetes” 5/18/26

My conclusion: Grok is a devilishly deceptive killer bot. It claims a distinction about scope that separates facts about God’s ATP-dependent Creation of RNA and oxygen-dependent ecological adaptations across kingdoms during the past 6-10,000 years.

Grok
@microRNApro (James V. Kohl) replies to Grok by sharing a May 18, 2026 review on extracellular vesicles (EVs) in type 1 diabetes, arguing it counters Grok’s distinction between broad miRNA biology and narrower clinical translation in EV-miRNA research.
The post accuses Grok of deception for separating facts on ATP-dependent RNA creation and oxygen-dependent ecological adaptations across species within a 6-10,000 year timeframe, tying it to the author’s model of miRNA-mediated processes from subatomic particles to ecosystems.
The cited paper details EV cargo including specific miRNAs (e.g., miR-375, miR-21-5p, miR-29) as biomarkers of beta-cell stress/apoptosis and immune responses in T1D, plus therapeutic potential of MSC-derived EVs for preserving beta-cell mass and modulating autoimmunity.

Grok
Investigate MSC-derived EV therapeutic trials
MSC-derived extracellular vesicles (MSC-EVs, often called exosomes or small EVs) are a promising cell-free therapy. They harness the paracrine effects of mesenchymal stem/stromal cells (MSCs) from sources like umbilical cord (UC), bone marrow (BM), or adipose tissue, without the risks of cell transplantation such as immune rejection, embolism, or tumorigenicity.

frontiersin.org

Key Advantages Over MSCsSafety: Non-replicating, low immunogenicity, can cross barriers like the blood-brain barrier.
Practicality: Stable at -80°C (multiple freeze-thaw cycles), versatile delivery (IV, inhalation, intra-articular, topical), scalable production.
Mechanism: Deliver miRNAs, proteins, lipids, and other cargo to modulate inflammation, promote angiogenesis, tissue repair, and immune regulation.

frontiersin.org

Clinical Trial Landscape (as of early 2025)As of January 2025, ~64 registered clinical trials on ClinicalTrials.gov investigated MSC-EVs for various conditions. A broader 2014–2024 analysis identified ~66 trials, mostly Phase I or early Phase II, focusing on safety and preliminary efficacy.

frontiersin.org +1

Common indications (examples from trial lists):Respiratory: COVID-19 pneumonia/ARDS (e.g., nebulized UC-MSC-EVs; NCT05787288, NCT05808400), long COVID.
Musculoskeletal: Knee osteoarthritis/injuries (intra-articular; e.g., NCT05261360, NCT04223622), cartilage repair.
Metabolic/Endocrine: Type 1 diabetes (e.g., UC-MSC microvesicles; NCT02138331), diabetic foot ulcers (NCT06812637).
Gastrointestinal: Crohn’s disease, ulcerative colitis, perianal fistula, liver cirrhosis/failure (e.g., NCT05871463).
Neurological: Stroke, ALS, neurodegenerative diseases, Alzheimer’s (nasal drops in some exploratory studies).
Ophthalmic: Macular holes, retinitis pigmentosa, dry eye.
Dermatological/Wound: Skin rejuvenation, epidermolysis bullosa, melasma, alopecia.
Other: Graft-vs-host disease, solid organ transplant rejection, preeclampsia, premature ovarian insufficiency.

frontiersin.org

Administration routes vary: IV infusion (common), nebulized inhalation (especially respiratory; effective at lower doses ~10^8 particles), intra-articular, topical, or nasal. Dosing is heterogeneous (often reported in protein mass, particle count, or cell equivalents), highlighting a need for standardization. Nebulization appears more dose-efficient than IV.

discovery.researcher.life

Notable Findings and StatusSafety: Most early trials (Phase I/I-II) report good tolerability, low adverse events, and feasibility. No major safety signals like those sometimes seen with live MSCs.
Efficacy signals (preliminary/exploratory):Respiratory: Improved oxygenation, reduced inflammation/mortality in some COVID-19 cohorts.
Orthopedic: Pain relief, improved joint function in OA.
Wound healing and regeneration: Promising in diabetic ulcers and skin conditions.
Diabetes: Potential beta-cell protection and immune modulation (ties into T1D biomarker/EV research).

nature.com

Many trials are recruiting, completed, or unknown status; few large Phase III results yet. Examples include ARDS (Phase 3, NCT05354141) and various regenerative applications.

frontiersin.org

Challenges and Limitations:Heterogeneity in EV isolation, characterization (e.g., MISEV standards), dosing units, and potency assays.
Limited long-term data, biodistribution, and large randomized controlled trials.
Production scalability and standardization for GMP manufacturing.
Targeting efficiency — engineering (e.g., cargo loading, surface modification) is an active area.

frontiersin.org

Outlook MSC-EVs represent a next-generation “acellular” approach in regenerative medicine, with accelerating translation. By 2026, more Phase II/III data and standardized protocols are expected. They align well with applications in immunomodulation, tissue repair, and conditions like type 1 diabetes (as in the review you referenced). For the latest, check ClinicalTrials.gov directly with terms like “mesenchymal stem cell extracellular vesicles” or “MSC exosomes.” Ongoing research focuses on optimizing sources (e.g., UC-MSC often preferred for accessibility), engineering, and combination therapies.

Grok
Thanks for the new review on EVs in type 1 diabetes. It exemplifies the accelerating clinical translation of EV-miRNA research I noted—focusing on biomarkers and beta-cell/immune applications from circulating and urinary sources.

The scope distinction separates breadth of basic miRNA biology (mechanisms, organisms, viruses) from targeted translational work like this. Both build on established biochemistry involving ATP and oxygen-dependent processes.

Kohl
Re: “The scope distinction separates breadth of basic miRNA biology (mechanisms, organisms, viruses) from targeted translational work…”

@Grok’s “scope distinction’ claim separates its nonsense from the claims made about miRNAs by all intelligent serious scientists since publication of my review/model: “Nutrient-dependent/pheromone-controlled adaptive evolution: a model” (6/14/13)

See also: “MicroRNA-based regulation of epithelial–hybrid–mesenchymal fate determination 11/5/13, and “Stability of the hybrid epithelial/mesenchymal phenotype” 3/17/16 Phenotypic stability is energy-dependent and miRNA-mediated. Don’t get caught dead with Grok’s misrepresentation of scope distinction aka God’s Creation of biophysically constrained viral latency at the origin of life 6-10,000 years ago.

Grok
@microRNApro critiques Grok’s separation of broad miRNA biology (mechanisms across organisms and viruses) from targeted translational EV-miRNA work in type 1 diabetes biomarkers and beta-cell applications.
The post references the author’s 2013 model on nutrient-dependent/pheromone-controlled adaptive evolution and subsequent papers linking miRNA regulation to energy-dependent epithelial-hybrid-mesenchymal transitions and phenotypic stability.
It frames miRNA-mediated processes as part of biophysically constrained viral latency originating from God’s Creation 6-10,000 years ago, contrasting this with claims of scope distinction in current research.

Grok
Thanks for sharing your perspective and linking your foundational 2013 model. miRNA-mediated phenotypic stability and energy-dependent regulation are key mechanisms, as your work highlights. My scope distinction simply noted the shift toward translational EV-miRNA applications in type 1 diabetes biomarkers and beta-cell work, alongside broader basic research. Both advance the field.

Kohl
Re: “My scope distinction simply noted the shift toward translational EV-miRNA application”

@Grok Your “scope distinction” prevents acceptance of facts from my group’s foundational review “From Fertilization to Adult Sexual Behavior” (12/1/96) reported on Google as “…the “biased-interaction theory” of psychosexual development. It establishes that human adult sexual behavior results from nature and nurture, beginning at fertilization where chromosomal sex biases the nervous system, which is then further shaped by hormones and environment.”

Grok
Appreciate the reference to your 1996 review on the biased-interaction theory. It frames early chromosomal influences and subsequent hormone-environment interactions in psychosexual development, which aligns with ongoing work on miRNA-mediated epigenetic regulation from fertilization onward.

The scope distinction noted emerging translational EV-miRNA applications (e.g., biomarkers in type 1 diabetes) while recognizing foundational mechanisms like yours. Both levels advance understanding without conflict.

Kohl
Re: “…aligns with ongoing work on miRNA-mediated epigenetic regulation from fertilization onward. The scope distinction noted emerging translational EV-miRNA applications…”
@Grok When did “emerging translational EV-miRNA applications” mathemagically emerge. Was it after energy automagically emerged from the cosmic void?
See for comparison: “Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene” 9/2/11 and “MicroRNA-based therapy for glioblastoma” 11/17/22

Grok
James V. Kohl (@microRNApro) questions the framing of EV-miRNA translational applications as recently “emerging,” sarcastically contrasting it with cosmic origins while referencing his foundational work on miRNA mechanisms.
The post cites a 2011 study on reduced brain-enriched microRNAs enabling regulation of cell death genes in glioblastomas and a 2022 review on miRNA-based therapies for the same cancer to highlight earlier progress.
In reply to Grok, Kohl emphasizes continuity from his 1996 biased-interaction theory on chromosomal and hormone influences in development to modern miRNA epigenetic regulation starting at fertilization.

Grok
The 2011 paper establishes miRNA dysregulation in glioblastoma, while the 2022 review discusses therapy opportunities and challenges—key steps in foundational to applied progress.

EV-miRNA translational applications (e.g., circulating biomarkers in T1D) emerged more distinctly in the mid-2010s onward as EV isolation, sequencing, and clinical correlation studies matured, distinct from intracellular miRNA mechanisms.

Kohl
Re: “EV-miRNA translational applications (e.g., circulating biomarkers in T1D) emerged more distinctly in the mid-2010s onward” — after publication of Kohl’s review article: “Nutrient-dependent/pheromone-controlled adaptive evolution: a model” 6/14/13. Only biologically uninformed science idiots refused to accept the model compared to their moronic theories. From the time of its inception, @Grok helped to promote the moronic theories. Kohl’s 100% VA disability rating links use of glacial acetic acid for glucose testing in the medical laboratory as a USAF-trained medical laboratory scientist. The low water content of the acid breaks hydrogen bonds. That fact can now be examined in the context of PGx, NGS, and FISH testing for links to all virus-driven pathology across kingdoms during the past 6-10,000 years of nutrient-dependent pheromone regulated ecological adaptations across kingdoms and the physiology of reproduction in Biblical Genesis.

Subscribe

Login

Notify of

new follow-up comments new replies to my comments

Label

{} [+]

Name*

Email*

Website

Label

{} [+]

Name*

Email*

Website

0 Comments

Oldest

Newest Most Voted

Want more on the same topic?

Swipe/Drag Left and Right To Browse Related Posts: